Newsroom

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Releases Regular Weekly Net Asset Value and Year-To-Date Return As Of 7 July 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) today released its regular weekly Net Asset Value (“NAV”) and performance returns on its website, https://pershingsquareholdings.com/performance/net-asset-value-and-returns/. The NAV and returns were computed as of the close of business on Tuesday, 7 July 2026. PSH NAV per share as of close of business on 7...

LONDON--(BUSINESS WIRE)--  Commonwealth Bank of Australia Issue of AUD 40,000,000 Floating Rate Notes due 8 October 2031 Series 6446 Tranche 1 MTN ISSUE NAME. Our Ref. MO0810 ISIN Code. XS2395556082 TOTAL INTEREST AMT. CURRENCY CODE. AUD DAY BASIS. ACTUAL/365 FIXED (A005) NUM OF DAYS. 92 INTEREST RATE. 5.1438 PCT VALUE DATE. 08/10/2026 INTEREST PERIOD. 08/07/2026 TO 08/10/2026 AUD 518,607.78 POOL FACTOR. N/A...

LONDON--(BUSINESS WIRE)--  Oberon AIM VCT plc ("OVCT" or the "Company") Director/PDMR Dealing The Company has been notified that on 8 July 2026, Geoffrey Gamble, Chairman of the Company, acquired 25,000 ordinary shares of 10.0p each in the Company ("Ordinary Shares") at a price of 20.25p per share. Following this transaction, Geoffrey Gamble’s beneficial interest is 340,290 Ordinary Shares which equates to 4.37% of the issued share capital of the Company. The Company has also been notified that...

LONDON--(BUSINESS WIRE)--  Commonwealth Bank of Australia Issue of USD 30,000,000.00 Floating Rate Notes due 15 January 2033 Series no 6657 Tranche 1 MTN ISSUE NAME. Our Ref. MS3157 ISIN Code. XS2977999593 TOTAL INTEREST AMT. CURRENCY CODE. USD DAY BASIS. 30/360 BOND BASIS (A001) NUM OF DAYS. 90 INTEREST RATE. 5.23446 PCT VALUE DATE. 15/07/2026 INTEREST PERIOD. 15/04/2026 TO 15/07/2026 USD 392,584.5 POOL FACTOR. N/A...

LONDON--(BUSINESS WIRE)--  Santander UK PLC Issue of GBP 1,250,000,000.00 Floating rate covered bond due July 2027 Series 84 Tranche 1 MTN ISSUE NAME. Our Ref. MQ4915 ISIN Code. XS2747638257 TOTAL INTEREST AMT. CURRENCY CODE. GBP DAY BASIS. ACTUAL/365 FIXED (A005) NUM OF DAYS. 91 INTEREST RATE. 4.2876 PCT VALUE DATE. 13/07/2026 INTEREST PERIOD. 13/04/2026 TO 13/07/2026 GBP 13,362,041.1 POOL FACTOR. N/A...

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN : FR0010120402 ; Mnemo : ALTHE), société innovante développant Sonovein®, une plateforme robotique pour la thérapie non invasive des varices par ultrasons focalisés de haute intensité (HIFU), annonce que son Conseil d’Administration, réuni le 8 juillet 2026, a nommé Monsieur Vincent Gardès en qualité de Président du Conseil d’Administration, avec effet immédiat. Administrateur de Theraclion depuis l’Assemblée Générale du 18 ju...

LONDON--(BUSINESS WIRE)--  Santander UK PLC Issue of GBP 1,500,000,000.00 Floating Rate Covered Bonds due Jan 2028 Series 80 Tranche 1 MTN ISSUE NAME. Our Ref. MP2432 ISIN Code. XS2574480708 TOTAL INTEREST AMT. CURRENCY CODE. GBP DAY BASIS. ACTUAL/365 FIXED (A005) NUM OF DAYS. 91 INTEREST RATE. 4.3976 PCT VALUE DATE. 13/07/2026 INTEREST PERIOD. 13/04/2026 TO 13/07/2026 GBP 16,445,819.18 POOL FACTOR. N/A...

MALAKOFF, France--(BUSINESS WIRE)--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), announces that its Board of Directors, which met on July 8, 2026, has appointed Mr. Vincent Gardès as Chairman of the Board of Directors, with immediate effect. A Director of Theraclion since the General Meeting of June 18, 2026, after having served...

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares and Weekly Summary of Transactions in Own Shares – 8 July 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 8 July 2...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to Week 140 compared with placebo. In this contemporary patient population treated with standard of care, includin...